Harlow, UK 02 October 2007 - Argenta Discovery Ltd., the pharmaceutical R&D group, has announced that it has entered into a fee-for-service collaboration with CellCentric Ltd. Under the terms of the agreement, scientists from the two companies will exploit Argenta's expertise in virtual screening, molecular biology, biochemical assay development and in vitro screening to discover inhibitors for two potential epigenetic-related therapeutic targets.
